Making data broadly available to clinicians and researchers has always been a part of the mission for Foundation Medicine Inc., said Michael Pellini, the company’s CEO.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
